Business Description
ISIN : US05352A1007
Total Employee Number:
13,500Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.08 | |||||
Equity-to-Asset | 0.49 | |||||
Debt-to-Equity | 0.66 | |||||
Debt-to-EBITDA | 32.75 | |||||
Interest Coverage | 2.94 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 1.79 | |||||
Beneish M-Score | -2.63 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -4.5 | |||||
3-Year EBITDA Growth Rate | -55 | |||||
3-Year EPS without NRI Growth Rate | -13.9 | |||||
3-Year FCF Growth Rate | -11.4 | |||||
3-Year Book Growth Rate | 4.3 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 2.1 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 72.55 | |||||
9-Day RSI | 70.16 | |||||
14-Day RSI | 69.37 | |||||
3-1 Month Momentum % | 35.74 | |||||
6-1 Month Momentum % | 37.24 | |||||
12-1 Month Momentum % | -5.98 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.78 | |||||
Quick Ratio | 1.18 | |||||
Cash Ratio | 0.22 | |||||
Days Inventory | 65.81 | |||||
Days Sales Outstanding | 61.7 | |||||
Days Payable | 59.09 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.4 | |||||
Shareholder Yield % | 5.9 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 31.83 | |||||
Operating Margin % | 7.45 | |||||
Net Margin % | -8.81 | |||||
EBITDA Margin % | 1.72 | |||||
FCF Margin % | 6.93 | |||||
OCF Margin % | 9.1 | |||||
ROE % | -10.09 | |||||
ROA % | -4.86 | |||||
ROIC % | 4.48 | |||||
3-Year ROIIC % | 22.38 | |||||
ROC (Joel Greenblatt) % | -20.04 | |||||
ROCE % | -2.98 | |||||
Years of Profitability over Past 10-Year | 6 | |||||
Moat Score | 7 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 18 | |||||
PS Ratio | 1.51 | |||||
PB Ratio | 1.75 | |||||
Price-to-Free-Cash-Flow | 21.76 | |||||
Price-to-Operating-Cash-Flow | 16.59 | |||||
EV-to-EBIT | -43.38 | |||||
EV-to-Forward-EBIT | 9.35 | |||||
EV-to-EBITDA | 117.38 | |||||
EV-to-Forward-EBITDA | 8.34 | |||||
EV-to-Revenue | 2.02 | |||||
EV-to-Forward-Revenue | 2.01 | |||||
EV-to-FCF | 29.15 | |||||
Price-to-GF-Value | 0.87 | |||||
Price-to-Projected-FCF | 0.9 | |||||
Earnings Yield (Greenblatt) % | -2.31 | |||||
FCF Yield % | 4.61 | |||||
Forward Rate of Return (Yacktman) % | -24.34 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:AVTR
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Avantor Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 6,561.1 | ||
| EPS (TTM) ($) | -0.84 | ||
| Beta | 1.0503 | ||
| 3-Year Sharpe Ratio | -0.2 | ||
| 3-Year Sortino Ratio | -0.31 | ||
| Volatility % | 50.6 | ||
| 14-Day RSI | 69.37 | ||
| 14-Day ATR ($) | 0.457973 | ||
| 20-Day SMA ($) | 13.9145 | ||
| 12-1 Month Momentum % | -5.98 | ||
| 52-Week Range ($) | 7.265 - 15.93 | ||
| Shares Outstanding (Mil) | 676.36 |
Piotroski F-Score Details
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Avantor Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Avantor Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-11 08:00 | In 166 days | ||
| Annual report for 2026 | 2027-02-11 | In 165 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-11 | In 165 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-29 08:00 | In 61 days | ||
| Third quarter earnings results for 2026 | 2026-10-29 | In 60 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-29 08:00 | 12.42 (+4.63%) | ||
| Second quarter earnings results for 2026 | 2026-07-29 | 12.42 (+4.63%) | ||
| General meeting for 2026 | 2026-05-07 11:00 | 8.43 (+0.36%) | ||
| First quarter earnings conference call for 2026 | 2026-04-29 08:00 | 7.86 (-1.38%) | ||
| First quarter earnings results for 2026 | 2026-04-29 | 7.86 (-1.38%) |
Avantor Inc Frequently Asked Questions
Guru Commentaries on NYSE:AVTR
Shares of life sciences supplier and distributor Avantor have been pressured by a sustained slowdown in life sciences demand and increased competition in its distribution business. While these dynamics may persist in the near term, we believe they are increasingly reflected in the current valuation.
Shares of Avantor declined 23% in the first quarter, as policy uncertainty around budget cuts for academic institutions and pharmaceutical companies weighed on the life sciences sector. With shares trading at valuations not previously seen in its history as a public company, we believe this is a dramatic overreaction as the market is essentially discounting a halting or meaningful slowdown in scientific progress at these levels. It is rare for companies benefiting from such strong secular growth trends to be valued at trough multiples on trough earnings, but that’s exactly how we view AVTR today, and exactly why we’ve capitalized on recent weakness to continue building our position.
Shares of Avantor declined 23% in the first quarter, as policy uncertainty around budget cuts for academic institutions and pharmaceutical companies weighed on the life sciences sector. With shares trading at valuations not previously seen in its history as a public company, we believe this is a dramatic overreaction as the market is essentially discounting a halting or meaningful slowdown in scientific progress at these levels. It is rare for companies benefiting from such strong secular growth trends to be valued at trough multiples on trough earnings, but that’s exactly how we view AVTR today, and exactly why we’ve capitalized on recent weakness to continue building our position.
Shares of Avantor declined 23% in the first quarter, as policy uncertainty around budget cuts for academic institutions and pharmaceutical companies weighed on the life sciences sector. With shares trading at valuations not previously seen in its history as a public company, we believe this is a dramatic overreaction as the market is essentially discounting a halting or meaningful slowdown in scientific progress at these levels. It is rare for companies benefiting from such strong secular growth trends to be valued at trough multiples on trough earnings, but that’s exactly how we view AVTR today, and exactly why we’ve capitalized on recent weakness to continue building our position.
Avantor is a global provider of essential products and services for the life sciences, advanced technologies and applied materials industries. Shares underperformed as most of its end markets remained soft.
Avantor is a global provider of essential products and services for the life sciences, advanced technologies and applied materials industries. Shares underperformed as most of its end markets remained soft.
Avantor is a global provider of essential products and services for the life sciences, advanced technologies and applied materials industries. Shares underperformed as most of its end markets remained soft.
Press Release
Articles on Avantor Inc
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
